• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

    5/19/26 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email

    SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.

    Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.

    At the same time, the use of wearable technology to track sleep is on the rise, increasing from 16% of adults in 20252 to 53% in 2026.3 Insights from wearable devices, including Oura Ring, can help people better understand their sleep patterns and encourage them to have informed conversations with their healthcare providers to learn more about potential sleep disorders, including obstructive sleep apnea (OSA). OSA is a chronic condition that disrupts breathing during sleep and often goes undiagnosed. In the U.S., an estimated 80% of people with OSA remain undiagnosed and untreated.4 Resmed and Oura are partnering to help close the awareness gap, turning insight into action.

    Oura Members who experience a higher number of nighttime breathing disturbances can easily connect to trusted resources from Resmed, including:

    • Educational resources and a sleep assessment to understand more about sleep health.
    • The option to connect with an independent healthcare provider, virtually or in-person, to address their sleep concerns.
    • An informative guide to support discussions with their healthcare provider.

    By connecting consumer-generated wellness insights with Resmed's sleep health resources, Resmed and Oura are helping Oura Members take a more informed next step to better understand their sleep health.

    "We're at an inflection point in how people engage with their sleep health, driven by rising awareness and more accessible technology," said Dr. Carlos Nunez, chief medical officer at Resmed. "By partnering with ŌURA, we are turning insight into action by guiding people across their sleep health journey and making it easier for them to seek clinical evaluation and care if they have concerns about their sleep."

    "High-quality sleep is one of the strongest foundations for long-term health, yet many people live for years with unrecognized sleep and breathing issues," said Dr. Ricky Bloomfield, chief medical officer at Oura. "By pairing Oura's continuous insights into sleep and nighttime breathing with Resmed's sleep expertise, we're giving people clearer tools and education to spot when something might be off and to more easily access care so they can better understand and act on changes in their sleep health."

    Resmed's connection with Oura is designed to reach individuals who may not recognize their sleep issues or engage with the healthcare system, making it easier for people to learn about their sleep health and connect with clinical resources when they need it. The experience is available to users of Oura Ring Gen3 and Oura Ring 4 who have an active Oura Membership in the U.S.

    About Resmed

    Resmed (NYSE:RMD, ASX: RMD)) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.

    About ŌURA

    ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission to shift healthcare from sick care to prevention, ŌURA supports millions of members worldwide across sleep, activity, stress, readiness, women's health, and heart health. Scientifically validated against medical gold standards, the lightweight Oura Ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, and organizations. With 1,000 ecosystem partners across wellness and medicine, ŌURA is advancing the future of preventative health.

    Founded in Finland in 2013, ŌURA has U.S. headquarters in San Francisco and E.U. headquarters in Oulu. ŌURA was last valued at approximately $11B—making it the world's most valuable standalone wearable company. Learn more at ouraring.com or connect with ŌURA on Instagram, LinkedIn, and TikTok.

    Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.

    Contacts 
      
    Resmed 
      
    For MediaFor Investors
    Caela ShaySalli Schwartz
    Caela.shay@resmed.comSalli.Schwartz@resmed.com
    news@resmed.cominvestorrelations@resmed.com
      
    Oura 
    press@ouraring.com 
      

    1 Resmed Global Sleep Survey 2026. Available at: sleepsurvey.resmed.com

    2 Resmed Global Sleep Survey 2025. Available at: sleepsurvey.resmed.com

    3 Resmed Global Sleep Survey 2026. Available at: sleepsurvey.resmed.com

    4 Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice. Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017



    Primary Logo

    Get the next $RMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    7/16/2026$234.00Outperform → Sector Perform
    RBC Capital Mkts
    7/13/2026$235.00Buy → Neutral
    Citigroup
    6/17/2026$230.00Overweight → Equal-Weight
    Morgan Stanley
    4/15/2026Overweight
    Analyst
    12/16/2025$275.00Outperform → Neutral
    Robert W. Baird
    9/18/2025$330.00Buy
    Citigroup
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    7/9/26 7:40:12 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    6/9/26 2:26:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)

    4 - RESMED INC (0000943819) (Issuer)

    6/3/26 3:45:27 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    SEC Filings

    View All

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - RESMED INC (0000943819) (Filer)

    7/7/26 5:24:32 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by ResMed Inc.

    144 - RESMED INC (0000943819) (Subject)

    7/7/26 10:07:44 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by ResMed Inc.

    SD - RESMED INC (0000943819) (Filer)

    5/26/26 4:30:09 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Announces Agreement to Sell MatrixCare Business

    SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-

    7/7/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location:         https://investor.resmed.comDate:               Thursday, August 6, 2026Time:               1:30 p.m. PT / 4:30 p.m. ETInternational:   London, Thursday, August 6, 2026, 9:30 p.m. BST                        Sydney, Friday

    6/30/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $234.00

    7/16/26 8:47:08 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed downgraded by Citigroup with a new price target

    Citigroup downgraded ResMed from Buy to Neutral and set a new price target of $235.00

    7/13/26 9:02:22 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded ResMed from Overweight to Equal-Weight and set a new price target of $230.00

    6/17/26 8:14:45 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location:         https://investor.resmed.comDate:               Thursday, August 6, 2026Time:               1:30 p.m. PT / 4:30 p.m. ETInternational:   London, Thursday, August 6, 2026, 9:30 p.m. BST                        Sydney, Friday

    6/30/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%GAAP income from operations increased 17%; non-GAAP income from operations up 18%GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2026.

    4/30/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

    SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.  "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat

    4/30/26 4:10:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care